FDA approves use of Boston Scientific DBS system during full-body MRI scans

“Boston Scientific continually strives to deliver new solutions that advance the field of neuromodulation and most importantly, result in better outcomes for our patients around the world,” Maulik Nanavaty, senior vice president and president of neuromodulation at Boston Scientific, said in a prepared statement.

“When evaluating which DBS system is best for each of my patients, I always consider the immediate and long term needs my patient might have so that we can effectively address a patient's therapeutic needs even as their disease progresses,” Robert Gross, MD, PhD, of Emory University in Atlanta, said in the same statement. “Customizable therapy, battery life, the size of the device, and access to MRI are factors patients should talk to their doctor about when they are considering deep brain stimulation.”